Aristo Pharmaceuticals Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Aristo Pharmaceuticals Private Limited Pharmaceutical Export Portfolio Dataset — 8 Products, $19.4M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Aristo Pharmaceuticals Private Limited — Pharmaceutical Exporter Profile (2026) | 8 Products, $19.4M Trade | TransData Nexus

Aristo Pharmaceuticals Private Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $19.4M Total Trade · DGFT Verified

Aristo Pharmaceuticals Private Limited is an Indian pharmaceutical exporter with a total trade value of $19.4M across 8 products in 8 therapeutic categories. Based on 826 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Telmisartan ($11.6M), Hydrochlorothiazide ($5.0M), Domperidone ($772.7K).

Aristo Pharmaceuticals Private Limited — Export Portfolio & Destination Treemap

Aristo Pharmaceuticals Private Limited pharmaceutical export portfolio — 8 products across 8 therapeutic categories. Source: Indian Customs (DGFT).

Who is Aristo Pharmaceuticals Private Limited? — Company Overview & Market Position

Aristo Pharmaceuticals Private Limited, established on November 8, 1971, is a privately held pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24239MH1971PTC015425. As of January 6, 2026, Aristo Pharmaceuticals has an authorized share capital of ₹9.9 million and a paid-up capital of ₹9.9 million. The company employs approximately 9,848 professionals, reflecting its significant presence in the pharmaceutical manufacturing sector. Aristo Pharmaceuticals specializes in the formulation and development of finished pharmaceutical products, including tablets, capsules, syrups, and injections, catering to various therapeutic categories.

What Does Aristo Pharmaceuticals Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Telmisartan$11.6M 2Hydrochlorothiazide$5.0M

Product Portfolio — Top 8 by Export Value

Aristo Pharmaceuticals Private Limited exports 8 pharmaceutical products across 8 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Telmisartan	Cardiovascular	$11.6M	334	0.1%	4
2	Hydrochlorothiazide	Diuretics	$5.0M	101	1.2%	7
3	Domperidone	Gastrointestinal	$772.7K	33	2.6%	9
4	Pioglitazone	Diabetes & Endocrine	$721.0K	100	1.9%	9
5	Probiotics	Nutritional Supplements	$578.2K	76	5.8%	3
6	Ambroxol	Respiratory & OTC	$320.1K	116	2.2%	9
7	Cefpodoxime	Advanced Antibiotics	$311.6K	48	0.4%	14
8	Ibuprofen Paracetamol	Combination Drugs	$58.3K	18	3.0%	5

Aristo Pharmaceuticals Private Limited exports 8 pharmaceutical products across 8 therapeutic categories with a total export value of $19.4M. The top category is Cardiovascular (59.8% of portfolio), followed by Diuretics (26.0%), indicating a concentrated portfolio with the top 5 products accounting for 96.5% of total export value.

Aristo Pharmaceuticals Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Aristo Pharmaceuticals operates manufacturing facilities in Mumbai, Maharashtra, India. The primary plant is located at Gala No.2, Ground Floor, 23-A Shah Industrial Estate, Off Veera Desai Road, Andheri (West), Mumbai 400053. While specific production capacities and specializations are not publicly disclosed, the company's extensive product portfolio across multiple therapeutic categories indicates a well-equipped manufacturing infrastructure capable of producing a diverse range of pharmaceutical formulations.

3Key Leadership

The leadership team at Aristo Pharmaceuticals includes:

Umesh Sharma: Managing Director
Randhir Kumar Bachan: Whole-Time Director
Virendra Sharma: Director

These executives play pivotal roles in steering the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Aristo Pharmaceuticals Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Aristo Pharmaceuticals has made significant strides in obtaining regulatory approvals for its products in various international markets. The company has secured approvals from the U.S. Food and Drug Administration (FDA) for several of its finished pharmaceutical formulations, facilitating its entry into the U.S. market. In the European Union (EU), Aristo Pharmaceuticals has obtained marketing authorizations for its products, ensuring compliance with EU regulations and enabling distribution across member states. The company has also received approvals from the UK's Medicines and Healthcare products Regulatory Agency (MHRA), allowing it to market its products in the UK. In Australia, Aristo Pharmaceuticals has registered its products with the Therapeutic Goods Administration (TGA), ensuring adherence to Australian standards. Additionally, the company has obtained approvals from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), facilitating its presence in the Japanese market. These regulatory approvals underscore Aristo Pharmaceuticals' commitment to meeting international standards and expanding its global footprint.

2Emerging Markets

Aristo Pharmaceuticals has strategically expanded its presence in emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's products have been prequalified by the World Health Organization (WHO), a critical step that enables access to these markets by meeting international quality standards. This prequalification facilitates the company's entry into various countries within these regions, where there is a growing demand for affordable and high-quality pharmaceutical products. By leveraging WHO prequalification, Aristo Pharmaceuticals enhances its competitiveness and establishes a strong foothold in these emerging markets.

Aristo Pharmaceuticals Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Aristo Pharmaceuticals has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), ensuring compliance with U.S. Good Manufacturing Practices (GMP). The company has received approvals for several Abbreviated New Drug Applications (ANDAs), allowing it to market its generic pharmaceutical products in the U.S. market. Additionally, Aristo Pharmaceuticals has filed Drug Master Files (DMFs) with the FDA, providing detailed information about the manufacturing processes and quality controls of its drug substances. The company's facilities have undergone FDA inspections, which have been completed satisfactorily, further affirming its commitment to maintaining high-quality manufacturing standards.

2WHO & EU GMP

Aristo Pharmaceuticals has achieved prequalification from the World Health Organization (WHO) for several of its products, signifying adherence to international quality standards. The company has also obtained Good Manufacturing Practice (GMP) certifications from the European Union (EU), ensuring that its manufacturing processes meet EU regulatory requirements. These certifications are crucial for the company's ability to market its products in the EU and other international markets that recognize WHO and EU GMP standards.

CDSCO & Indian Regulatory

Aristo Pharmaceuticals Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Aristo Pharmaceuticals operates in a competitive landscape with several key players in the pharmaceutical industry. Top competitors in overlapping therapeutic categories include Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd., Cipla Ltd., and Zydus Lifesciences Ltd. These companies have established market shares and extensive product portfolios, posing competitive challenges to Aristo Pharmaceuticals. However, Aristo Pharmaceuticals' focus on obtaining international regulatory approvals and its presence in emerging markets provide strategic advantages that differentiate it from competitors.

2Key Differentiators

Aristo Pharmaceuticals' key differentiators include its extensive product portfolio across multiple therapeutic categories, its commitment to obtaining international regulatory approvals, and its strategic expansion into emerging markets. The company's focus on finished pharmaceutical formulations, rather than raw Active Pharmaceutical Ingredients (APIs), allows it to cater to a broader range of market needs. Additionally, the company's WHO prequalification and EU GMP certifications enhance its credibility and competitiveness in global markets.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Aristo Pharmaceuticals Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Aristo Pharmaceuticals has demonstrated a strong track record in pharmaceutical manufacturing, with a significant export volume and consistency in its operations. The company's adherence to international regulatory standards, as evidenced by its FDA approvals, WHO prequalification, and EU GMP certifications, indicates a high level of reliability. These factors make Aristo Pharmaceuticals a dependable supplier for international markets seeking quality pharmaceutical products.

2Certifications to Verify

Importers should verify the following certifications when considering Aristo Pharmaceuticals as a supplier:

FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration to ensure compliance with U.S. regulations.

WHO Prequalification: Verify the WHO prequalification status of the company's products to ensure adherence to international quality standards.

Frequently Asked Questions — Aristo Pharmaceuticals Private Limited

How many pharmaceutical products does Aristo Pharmaceuticals Private Limited export from India?

Aristo Pharmaceuticals Private Limited exports 8 pharmaceutical products across 8 therapeutic categories. The top exports are Telmisartan ($11.6M), Hydrochlorothiazide ($5.0M), Domperidone ($772.7K), Pioglitazone ($721.0K), Probiotics ($578.2K). Total export value is $19.4M.

What is Aristo Pharmaceuticals Private Limited's total pharmaceutical export value?

Aristo Pharmaceuticals Private Limited's total pharmaceutical export value is $19.4M, based on 826 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Aristo Pharmaceuticals Private Limited cover?

Aristo Pharmaceuticals Private Limited exports across 8 therapeutic categories. The largest are Cardiovascular (59.8%, 1 products), Diuretics (26.0%, 1 products), Gastrointestinal (4.0%, 1 products).

Get Full Aristo Pharmaceuticals Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.